You are right about TWH not doing the same business as AusCann. I have not dug into its past to find out why or whether TWH people continue to work in the new business. I only wanted to point out the cycle of failing, raising fund and relisting by acquisition a new line of business and go for IPO again ... This can potentially fool a lot of new investors to part with their money. But I feel (IMHO) that AusCann does not really have a product at all. It seems all talk and no show. In the interview and other videos, Elaine never showed the audience any R&D facilities, labs, products and introduced the technical workers ... I think it has now contracted the design of a product to PCI Pharma. If it had the blue print of a product, they would have a small quantity already produced in its own lab and further more produced at PCI Pharma as trial run by now. The complete lack of arrangement for trials further raised the doubt. I am surprised that no analyst has raised these issues.
AC8 Price at posting:
48.0¢ Sentiment: None Disclosure: Not Held
